Revelation Biosciences (REVB) AI Stock Analysis

• Market Cap: $4.54M
• Dividend Yield: N/A
• Average Volume (3M): 740.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: N/A
• EPS Growth: 96.26%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 3,720,420
• 10 Day Avg. Volume: 239,834
• 30 Day Avg. Volume: 740,557
• PEG Ratio: 0.03
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -2.19K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 1.70M
• Enterprise Value/Ebitda: -550.31
• 1Y Price Target: $16.00
• Price Target Upside: 1677.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -14.32
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.00 ▲(11.11% Upside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is primarily constrained by weak financial performance—no revenue, persistent losses, and accelerating cash burn—raising ongoing funding risk. Technicals are also unfavorable with a clear downtrend and negative momentum indicators, despite oversold readings. Valuation provides limited support due to negative earnings and no dividend yield.

Positive Factors

Targeted innate-immunity pipeline

A focused clinical-stage platform targeting innate immunity creates a durable strategic niche across respiratory viral infections and related indications. This platform orientation supports repeatable R&D application, potential multi-indication value capture, and clearer prioritization of clinical resources over the next 2–6 months.

Modest leverage

Low reported debt relative to equity provides structural financial flexibility for a pre-revenue biotech. With modest leverage, the company faces lower fixed interest burdens, preserving its ability to prioritize R&D spend and access capital markets without immediate solvency pressure over the medium term.

Completed warrant financing

A recent warrant inducement that generated ~$7.3M materially extends near-term runway and demonstrates management's ability to secure non-dilutive-today cash via financings. This structural capital infusion increases probability of advancing clinical milestones before next major financing, improving program continuity.

Negative Factors

Pre-revenue profile

No product revenue leaves the company fully dependent on external capital to fund operations and trials. This structural reliance increases dilution and execution risk over time, reducing visibility into sustainable cash generation and making long-term planning contingent on successful raises or partnerships.

Persistent cash burn

Sustained negative operating and free cash flow, with a marked deterioration in the latest year, signals ongoing heavy R&D and operating outflows. This durable cash burn pattern necessitates frequent financing, compresses optionality for program prioritization, and elevates execution risk absent new funding.

Financial statement discontinuity

A material YoY discontinuity in equity and assets increases uncertainty about comparability and underlying financial stability. Such structural reporting shifts complicate forecasting, hinder trend analysis for investors and partners, and raise governance or accounting risk that can affect capital access.

Revelation Biosciences Business Overview & Revenue Model

Company Description

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

How the Company Makes Money

null

Revelation Biosciences Financial Statement Overview

Summary

Pre-revenue profile with persistent and worsening losses and a material deterioration in operating/free cash flow in the latest period. While leverage appears modest, the scale-up in cash burn and profitability deterioration increases funding and sustainability risk.

Income Statement

The company reports no revenue across all provided annual periods, which is common in early-stage biotech but materially limits earnings quality and visibility. Losses are persistent and sizable, with net income negative each year; the 2025 annual period shows an extreme step-up in losses versus prior years, indicating a sharp deterioration in profitability and cost discipline. With zero revenue, margins are not informative, and the overall earnings trajectory is unfavorable.

Balance Sheet

Leverage appears modest in the latest annual period (debt is low relative to equity), which is a balance-sheet positive. However, returns on equity are consistently negative, reflecting ongoing losses and weak capital efficiency. There is also a major year-over-year discontinuity in reported equity and assets in 2025 versus 2024, which increases uncertainty around comparability and underlying financial stability.

Cash Flow

Cash burn is significant and ongoing: operating cash flow and free cash flow are negative in every year provided, and the latest annual period shows a very large deterioration in absolute cash outflows. Free cash flow closely tracks net losses (little evidence of cash generation), and the business does not demonstrate a path to self-funding operations based on these statements.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-27.06K	0.00	0.00	0.00	0.00
EBITDA	18.14M	-7.95M	-8.63M	-10.84M	-11.93M
Net Income	-8.91M	-15.04M	-120.25K	-10.83M	-11.99M
Balance Sheet
Total Assets	11.58B	6.62M	12.21M	5.50M	2.04M
Cash, Cash Equivalents and Short-Term Investments	10.70B	6.50M	11.99M	5.25M	1.27M
Total Debt	746.78M	0.00	0.00	0.00	16.75K
Total Liabilities	2.72B	1.91M	5.56M	4.45M	2.14M
Stockholders Equity	8.86B	4.71M	6.65M	1.05M	-99.47K
Cash Flow
Free Cash Flow	-8.27B	-18.34M	-7.29M	-11.22M	-11.22M
Operating Cash Flow	-8.27B	-18.32M	-7.29M	-11.22M	-11.09M
Investing Cash Flow	0.00	-19.17K	0.00	0.00	-131.96K
Financing Cash Flow	12.47B	12.85M	14.03M	15.20M	8.00M

Revelation Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.92, and below the 200-day MA of 5.93, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 29.27 is Positive, neither overbought nor oversold. The STOCH value of 18.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REVB.

Revelation Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	47 Neutral	$4.45M	-0.76	-203.36%	―	―	90.53%
AZTR	43 Neutral	$4.81M	-0.12	-215.04%	―	-100.00%	93.82%
REVB	42 Neutral	$4.54M	-2.23	-0.40%	―	―	96.26%
GTBP	41 Neutral	$14.78M	-0.15	-356.99%	―	―	54.62%

Revelation Biosciences Corporate Events

Revelation Biosciences Shareholders Approve Warrant Share Issuance

On March 18, 2026, Revelation Biosciences held a Special Meeting of Stockholders at which investors approved the issuance of common shares underlying the Class J Common Stock Warrants, even if such issuance exceeds 20% of outstanding shares and would otherwise violate Nasdaq’s Exchange Cap rule. As a result, the Class J warrants, first issued on January 26, 2026 under a prior inducement arrangement, now have a confirmed expiration date of March 18, 2031, with the vote ensuring sufficient flexibility for future share issuance and capital-raising activities tied to these warrants.

At the Special Meeting, a quorum was achieved with 4,171,735 shares represented out of 10,492,469 eligible shares, and stockholders approved both the warrant-related share issuance and the discretionary authority to adjourn the meeting if needed to secure enough proxies. The strong majorities in favor of both proposals reinforce shareholder support for the company’s financing structure and provide management with added procedural and capital markets flexibility going forward.

The most recent analyst rating on (REVB) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.

Revelation Biosciences Raises Capital via Warrant Inducement

On January 23, 2026, Revelation Biosciences entered into inducement agreements with two holders of its existing Class I common stock warrants, leading to the immediate cash exercise of 8,544,999 pre-split (2,136,251 post-split) warrants at an effective post-split price of $3.44 per share, generating approximately $7.3 million in gross proceeds to support its clinical development plans, working capital and general corporate needs. In return, the company issued 17,089,998 pre-split (4,272,500 post-split) new Class J common stock warrants in a private placement exempt from registration, with the new warrants becoming exercisable for five years following stockholder approval, while Revelation agreed to file a resale registration statement for the underlying shares and pay Roth Capital Partners an 8% advisory fee; the company also clarified that an initially expected third investor ultimately withdrew, reducing the originally anticipated size of the transaction.

The most recent analyst rating on (REVB) stock is a Hold with a $0.51 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.